Who
Chris Calise
Director
Company insider
Files Form 4 as: Chief Financial Officer, Coeptis Therapeutics Holdings.
In numbers
- Trades disclosed
- 10
- Buys
- 1
- Sells
- 0
- Bought
- $11K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 Dec 2020
- Last trade
- 11 Feb 2026
- Last filed
- 13 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Feb 2026filed 13 Feb 2026 | Coeptis Therapeutics HoldingsConsumer & Specialty Finance | SEC FORM 4 Code M | $60K5,700 at $10.56 | filing |
| 11 Feb 2026filed 13 Feb 2026 | Coeptis Therapeutics HoldingsConsumer & Specialty Finance | SEC FORM 4 Code A | —3,250 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ZSQR Z SquaredConsumer & Specialty Finance | SEC FORM 4 Code M | $60K5,700 at $10.56 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ZSQR Z SquaredConsumer & Specialty Finance | SEC FORM 4 Code A | —3,250 at $0.00 | filing |
| 4 Mar 2025filed 6 Mar 2025 | ZSQR Z Squaredoption or derivative · Consumer & Specialty Finance | SEC FORM 4 Code A | —5,700 | filing |
| 23 Aug 2023filed 31 Aug 2023 | ZSQR Z SquaredConsumer & Specialty Finance | SEC FORM 4 Bought | $8,4609,000 at $0.94 | filing |
| 23 Aug 2023filed 31 Aug 2023 | ZSQR Z SquaredConsumer & Specialty Finance | SEC FORM 4 Bought | $2,4272,582 at $0.94 | filing |
| 27 Jan 2023filed 31 Jan 2023 | ZSQR Z Squaredoption or derivative · Consumer & Specialty Finance | SEC FORM 4 Code A | —30,000 | filing |
| 28 Oct 2022filed 1 Nov 2022 | ZSQR Z Squaredoption or derivative · Consumer & Specialty Finance | SEC FORM 4 Code A | $3.0M3,000,000 at $1.00 | filing |
| 14 Dec 2020filed 14 Dec 2020 | ZSQR Z SquaredConsumer & Specialty Finance | SEC FORM 4 Code J | —281,250 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.